Delving into the Latest Updates on Chlorpheniramine Maleate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1-(p-chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine, 1-(p-chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane, 2-[p-chloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine

+ [45]

Target

H1 receptor

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesCardiovascular Diseases+ [4]

Active Indication

Oedema vascularAngioedemaEczema+ [8]

Inactive Indication

Cutaneous hypersensitivityNeurodermatitisPhotosensitivity Disorders+ [1]

Originator Organization

Schering Plough A/S

Active Organization

Fuji Yakuhin Co., Ltd.

Alfresa Pharma Corp.

Tianjin KingYork Group Hubei Tianyao Pharmaceutical Co., Ltd.

+ [8]

Inactive Organization

Hubei Huazhong Pharmaceutical Co. Ltd.

Schering AG

Drug Highest PhaseApproved

First Approval Date

US (13 Jul 1949),

Urticaria

Regulation-

Login to view timeline

Structure

Molecular FormulaC20H23ClN2O4

InChIKeyDBAKFASWICGISY-BTJKTKAUSA-N

CAS Registry113-92-8

View All Structures (2)

The goal of this clinical trial is to learn about voice function before and 3 hours after administration of first generation over-the-counter antihistamine in individuals who have been medically diagnosed with allergies and routinely take over-the-counter (OTC) antihistamines for allergy symptoms. The main questions are:
Do first generation OTC antihistamines make voice function worse as measured via voice acoustic and aerodynamic measures? It is hypothesized that all objectives measures will reflect a negative change in voice function.
Do first generation OTC antihistamines make voice function worse as measured via participant and researcher perceptual measures? It is hypothesized that participants will rate their vocal function as more effortful after taking the antihistamine and researchers will rate voice quality as worse.
Participants ages 18-35 who have been diagnosed with allergies, are free of laryngeal pathology, and meet inclusion criteria will be consented. Participation in the study involves a pretrial visit and one day of data collection. The initial visit will obtain informed consent and train the trial measures. The 2nd day involves determination of systemic hydration (<1.02 g/ml), administration of the OTC antihistamine (Chlor-Trimeton), and measures taken at baseline and 3 hours after antihistamine administration. This antihistamine was selected for its lower sedation and anticholinergic effects than its other first-generation options. Each participant will take one, 12mg tablet. Onset action time for this antihistamine is 3 hours. Participants will be given water to consume during the 3 hour wait for the 2nd data time point to maintain hydration. Measures include routine clinical perceptual, acoustic, aerodynamic, and laryngeal imaging measures.

Start Date13 Jun 2023

Sponsor / Collaborator

Auburn University

100 Clinical Results associated with Chlorpheniramine Maleate

Login to view more data

100 Translational Medicine associated with Chlorpheniramine Maleate

Login to view more data

100 Patents (Medical) associated with Chlorpheniramine Maleate

Login to view more data

2,480

Literatures (Medical) associated with Chlorpheniramine Maleate

16 Dec 2024·Journal of Toxicology and Environmental Health, Part A

Effects of anthranilic diamide insecticides on metamorphosis in the common toad Rhinella arenarum (Hensel, 1867) at concentrations found in aquatic environments

Article

Author: Peña, Shirley Vivian Daniela Fonseca ; Brodeur, Julie Céline

Anthranilic diamides (AD) are a modern class of insecticides used as alternatives to pyrethroids and neonicotinoids, particularly against lepidopteran pests. Despite their widespread use and presence in surface waters, little is known regarding their effects on amphibians. The aim of this study was to examine the effects of environmentally-relevant concentrations of AD insecticides chlorantraniliprole (CHLO) and cyantraniliprole (CYAN) on metamorphosis of the toad Rhinella arenarum. Tadpoles were exposed to CHLO or CYAN at concentrations ranging from 5 and 5000 µg/L from stage 27 until metamorphosis completion. Both insecticides produced a non-monotonic acceleration of the time required for individuals to progress through development and a decrease in the proportion of individuals completing metamorphosis, although a delay in metamorphosis was also observed at 5 µg/L of CHLO. Snout-vent length and body weight of metamorphosed toads were not markedly affected by either insecticide. CHLO was more toxic than CYAN, with a lowest observed effect concentration (LOEC) for CHLO on time to metamorphosis defined as 5 µg/L compared to 5000 µg/L for CYAN. The LOEC for reduced metamorphic success defined as 50 µg/L for CHLO compared to 500 µg/L for CYAN. As most effects occurred after stage 39, when metamorphosis depends upon thyroid hormones, it is conceivable that that AD insecticides act as endocrine disruptors. These findings suggest that contamination of surface waters with CHLO and CYAN may disrupt amphibian development in the wild and warrant further research to investigate the possibility of endocrine-disruption by ADs.

01 Dec 2024·European Journal of Clinical Pharmacology

Preventive effects of first-generation antihistamine on emergence agitation or delirium: a systematic review

Review

Author: Matsunuma, Satoru ; Kotake, Kazumasa ; Noritake, Yumi ; Kitamura, Naoya ; Kawakami, Yasuhiro

PURPOSEThe effects of first-generation antihistamines in preventing postoperative emergence agitation or delirium are unclear. Determining the postoperative effects of first-generation antihistamines may provide important insights into the management of patient safety. Therefore, we performed a systematic review of randomized controlled trials (RCTs) evaluating the efficacy and safety of postoperative first-generation antihistamines.METHODSPatients who used first-generation antihistamines in the intensive care unit or operating room were included. Primary outcomes were assessed postoperative emergence agitation or delirium with binary and continuous variables. The secondary outcome was any adverse event.RESULTSNine studies were included. The frequency of postoperative emergence agitation, measured using binary variables, tended to be lower in patients receiving chlorpheniramine or diphenhydramine than those receiving saline. However, evaluation using the Richmond Agitation-Sedation Scale as a continuous variable revealed that only chlorpheniramine was effective at lowering postoperative emergence agitation. Only one study assessed delirium but found no benefit of first-generation antihistamines. Adverse events for first-generation antihistamines did not differ from that of other drugs.CONCLUSIONOur results provide limited evidence that some first-generation antihistamines may prevent postoperative emergence agitation and are safe. To further verify this possibility, new RCTs with clear and universal assessment criteria for postoperative emergence agitation or delirium should be conducted.

05 Nov 2024·Current Drug Safety

Carbamazepine-induced Stevens-Johnson Syndrome: A Case Report with Review of the Literature

Article

Author: Haitharali, Rajamohamed ; S, Nirenjen ; Raja, Sangeetha ; Dhansekaran, Sivaraman ; Manavalan, Mohankumar ; Subramanian, Arunkumar ; T, Tamilanban ; Gnanasekaran, Sabariakilesh

Background:Stevens-Johnson Syndrome (SJS) is an infrequent yet severe mucocutaneous reaction that involves less than 10% of the Body Surface Area (BSA). It is predominantly induced by certain medications, including anticonvulsants (e.g., Lamotrigine, Carbamazepine, Phenytoin, Phenobarbitone), Allopurinol at doses above 100 mg per day, and sulphonamides (e.g., Cotrimoxazole, Sulfasalazine). Genetic predispositions, particularly the presence of the HLA-B*1502 allele, significantly increase the risk of developing SJS. This case report discusses a unique presentation of SJS in a young female patient, emphasizing the critical need for genetic screening and careful monitoring when prescribing Carbamazepine, especially in populations at higher genetic risk.Case Presentation:A 19-year-old female patient, who had been on Phenytoin and Sodium Valproate for epilepsy management over the past year, was newly prescribed Carbamazepine. Within a week of initiating Carbamazepine, the patient experienced a seizure, followed by the sudden onset of fever, painful sores, and blisters covering the upper body, along with mucous discharge from both eyes. These symptoms rapidly worsened. Based on clinical presentations and the extent of epidermal detachment, the patient was diagnosed with SJS. The severity and mortality risks were assessed using the SCORTEN score. Therapeutic interventions included intravenous Ranitidine, Ondansetron, Paracetamol, Midazolam, Levetiracetam, and Dexamethasone, along with oral Fluconazole, Chlorpheniramine tablets, and Ciprofloxacin eye drops. The patient showed significant improvement and was discharged after fourteen days with followup advice.Conclusion:This case underscores the critical importance of performing genetic testing for the HLA-B*1502 allele and conducting baseline blood tests before initiating Carbamazepine therapy. Such precautionary measures can significantly mitigate the risk of severe adverse reactions like SJS. This report adds to the scientific literature by highlighting the potential dangers associated with anticonvulsant therapies and the necessity for personalized medicine approaches in preventing life-threatening conditions. The main takeaway is the pivotal role of genetic screening and vigilant monitoring in the management of patients requiring anticonvulsant medications to prevent serious adverse reactions.

1

News (Medical) associated with Chlorpheniramine Maleate

06 Sep 2023

·www.biospace.com

Dr. Ferrer Biopharma to Showcase Groundbreaking Research in Post-COVID Treatment at ERS Congress 2023

Intranasal Chlorpheniramine Shows Significant Promise in Mitigating Prolonged Post-COVID-19 Symptoms HALLANDALE BEACH, Fla.--(BUSINESS WIRE)-- Leading pharmaceutical research and development company Dr. Ferrer Biopharma proudly announces its participation in the highly anticipated European Respiratory Society (ERS) Congress 2023, scheduled in Milan, Italy, from September 9th to 13th. During the event, the company will present late-breaking findings from two randomized controlled trials that shed light on the potential of intranasal Chlorpheniramine to treat post-COVID-19 long-term symptoms. The ERS Congress serves as a premier platform in respiratory health, featuring the latest advancements in clinical care, scientific research, education, and technology, where experts and researchers worldwide share insights and discoveries, driving progress in respiratory medicine. Highlighting a pioneering study, the late-breaking abstract by Dr. Ferrer Biopharma introduces Intranasal Chlorpheniramine Maleate (iCPM) as an innovative therapeutic strategy with promising anti-inflammatory and antiviral properties against COVID-19 and respiratory viruses, specifically addressing long-term symptoms. Investigating the effects of this novel approach, Dr. Ferrer Biopharma's presentation delves into the impact of intranasal Chlorpheniramine on post-COVID-19 symptoms, revealing significant improvements in clinical recovery time and alleviation of symptoms like anosmia, ageusia, and cough, as demonstrated by the two randomized trials ACCROS I, and ACCROS III. The subsequent post-trial follow-up highlights Chlorpheniramine's remarkable reduction of post-COVID symptoms by over 90% compared to a placebo. "The antiviral and anti-inflammatory effect of iCPM can explain the significant impact in reducing time to clinical recovery in the acute illness," said Dr. Franck Rahaghi, Clinical Professor of Medicine and chairman of Cleveland Clinic Florida pulmonary and critical care department, who leads the study. "iCPM may have better impact in reducing long-COVID symptoms. This reformulated treatment could become a cornerstone intervention in addressing the dreaded issue of long-COVID." "We are excited to unveil the results of our comprehensive research that explores the impact of intranasal chlorpheniramine on post-COVID-19 long-term symptoms," said Dr. Fernando Valerio, Principal Investigator. The company's participation underscores its dedication to propelling innovation and achieving excellence in respiratory medicine. About Dr. Ferrer Biopharma: Dr. Ferrer Biopharma is a pioneering pharmaceutical research and development company dedicated to advancing intranasal medications for treating cough, colds, flu, and allergies. We use advanced technology to bring to the market high-quality, evidence-based, consumer-focused therapies that originated at the bedside. For more information, please visit DrFerrerBioPharma.com.

Clinical Study

100 Deals associated with Chlorpheniramine Maleate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Chlorpheniramine Maleate	R06AB04	DB01114

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Oedema vascular	JP	Fuso Pharmaceutical Industries Ltd.	31 Aug 2007
Angioedema	JP	Kowa Corp.	20 Jul 1984
Eczema	JP	Alfresa Pharma Corp.	24 Apr 1984
Rhinitis, Allergic	JP	Alfresa Pharma Corp.	24 Apr 1984
Drug Eruptions	CN	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1981
Drug Eruptions	CN	Tianjin KingYork Group Hubei Tianyao Pharmaceutical Co., Ltd.	01 Jan 1981
Drug Eruptions	CN	Grand Pharmaceutical (China) Co., Ltd.	01 Jan 1981
Drug Eruptions	CN	Tianjin Huajin Pharmaceutical Co. Ltd.	01 Jan 1981
Drug Eruptions	CN	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1981
Edema	JP	Nichi-Iko Pharmaceutical Co., Ltd.	27 Jan 1961
Pruritus	JP	Nichi-Iko Pharmaceutical Co., Ltd.	27 Jan 1961
Rhinitis, Allergic, Seasonal	JP	Nichi-Iko Pharmaceutical Co., Ltd.	27 Jan 1961
Rhinitis, Vasomotor	JP	Nichi-Iko Pharmaceutical Co., Ltd.	27 Jan 1961
Urticaria	US	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	HN	FERRER MEDICAL INNOVATIONS LLCStartup	27 Jul 2022
Urticaria	Phase 2	US	Schering AG	13 Jul 1949
Cutaneous hypersensitivity	Discovery	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	19 Feb 2019
Drug Eruptions	Discovery	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	19 Feb 2019
Eczema	Discovery	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	19 Feb 2019
Neurodermatitis	Discovery	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	19 Feb 2019
Photosensitivity Disorders	Discovery	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	19 Feb 2019
Pruritis (itchy skin)	Discovery	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	19 Feb 2019
Rhinitis, Allergic	Discovery	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	19 Feb 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


KCT0004880 (Pubmed \| J Anesth)	Not Applicable	Bladder Cancer	-	Chlorpheniramine group	vgijmkabhx(rysqfuweii) = rnamzaqpzx dqtccqgomk (qoxwdcrvdx )	Positive	10 Jul 2021
				Control group	vgijmkabhx(rysqfuweii) = vinohdrcmt dqtccqgomk (qoxwdcrvdx )
NCT03879772 (C95-161, CTgov)	Phase 3	Rhinitis, Allergic, Seasonal	679	Placebo nasal spray+Chlorpheniramine maleate syrup+Mometasone furoate nasal spray (MFNS 25 mcg QD)	lshniuputg(ptytdybsmt) = nzffwqgquz jkxwowtkjc (awlgcifloj, jqwtvlnqal - hcccbqznue) View more	-	12 Aug 2019
				Placebo nasal spray+Chlorpheniramine maleate syrup+Mometasone furoate nasal spray (MFNS 100 mcg QD)	lshniuputg(ptytdybsmt) = fxlczswfia jkxwowtkjc (awlgcifloj, yrmauzkmny - ppnpvrksee) View more
NCT04790487 (Pubmed \| Int J Clin Pharmacol Ther)	Phase 2/3	Common Cold \| Chronic rhinitis	24	Nasal chlorphenamine maleate 1.12 mg	(xkcrimtebf) = vwnguwjuwl ekkdduheog (hnpobqiebt ) View more	-	01 Apr 2001
				Nasal chlorphenamine maleate 2.24 mg	(xkcrimtebf) = tkzzyfqnmf ekkdduheog (hnpobqiebt ) View more